Liver Diseases (Liver Disease)

Subscribe to Selected New Research on Liver Diseases

20042 relevant articles (855 outcomes, 1837 trials/studies) found for this Disease

Description: Pathological processes of the LIVER.

Also Known As:

Liver Disease; Diseases, Liver; Liver Dysfunction; Disease, Liver; Dysfunction, Liver; Dysfunctions, Liver; Liver Dysfunctions

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infection
2.	Fibrosis (Cirrhosis)
3.	Hepatocellular Carcinoma (Hepatoma)
4.	Hepatitis B
5.	Hemorrhage

Experts

1.	Tacke, Frank: 12 articles (12/2007 - 04/2002)
2.	Trautwein, Christian: 12 articles (12/2007 - 04/2002)
3.	Manns, Michael P: 10 articles (08/2008 - 06/2002)
4.	Mieli-Vergani, Giorgina: 7 articles (02/2006 - 03/2002)
5.	Manns, M P: 7 articles (08/2004 - 09/2000)
6.	Mieli-Vergani, G: 6 articles (03/2002 - 02/2000)
7.	Dhawan, A: 5 articles (08/2008 - 03/2000)
8.	Lee, Shou-Dong: 5 articles (12/2007 - 05/2006)
9.	Huo, Teh-Ia: 5 articles (12/2007 - 05/2006)
10.	Dhawan, Anil: 5 articles (12/2007 - 06/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Liver Diseases:

1.	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 02/01/1994 - "Ursodeoxycholic acid has been reported to be beneficial for patients with various chronic cholestatic liver diseases. " 01/01/1994 - "BACKGROUND/AIMS: Ursodeoxycholic acid (UDCA) is clinically beneficial in chronic cholestatic liver disease, but the underlying mechanisms are unclear. " 02/01/2004 - "Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. " 02/01/2004 - "Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease." 09/24/1999 - "The therapeutic efficacy of ursodeoxycholic acid (UDCA) has been widely demonstrated in various liver diseases, suggesting that UDCA might protect hepatocytes against common mechanisms of liver damage. " Order ALL the reference details at left...
2.	InterferonsIBA 01/01/2001 - "The short courses of interferon monotherapy that were used in the early 1990s led to sustained improvement in liver disease and durable loss of detectable virus in fewer than 10% of patients. " 02/01/2000 - "Interferon monotherapy became clinically available 10 years ago but resulted in sustained improvement in liver disease and durable loss of detectable virus in fewer than 10% of treated patients. " 11/01/1995 - "Thus, longterm interferon treatment seems effective in clearing hepatitis C virus from serum of patients with chronic liver disease." 01/01/1990 - "These results indicate that interferon is effective in inducing clearance of HBV from serum and improvement of biochemical and histological parameters of liver disease. " 09/01/2003 - "In the absence of suitable animal models, HCV dynamic studies in man have been helpful in defining the mechanisms of action of interferon in chronic HCV liver disease. " Order ALL the reference details at left...
3.	Hepatitis B e AntigensIBA 01/01/1995 - "We now show that the number of amino acid substitutions in the HBV core is low in viral sequences from patients with HBeAg positive chronic liver disease and HBeAg negative HBeAb positive patients in remission, but the frequency of substitutions is high in HBeAg, negative HBeAb positive patients with active liver disease. " 09/01/2006 - "Courses of finite duration, aiming to achieve sustained off-therapy responses, are practically restricted to HBeAg+ patients with compensated chronic liver disease, whereas long-term therapy aiming to achieve maintained on-therapy remission is mostly applicable to HBeAg- individuals either with early or advanced liver disease. " 07/01/1996 - "Conversely about 90% of children infected later in life clear HBeAg and achieve sustained remission of liver disease before reaching adulthood. " 03/01/2007 - "These will be followed eventually by HBeAg seroconversion, which is usually accompanied by remission of liver disease and confers favourable outcome. " 09/01/2009 - "Spontaneous HBeAg seroconversion is usually accompanied by liver disease remission. " Order ALL the reference details at left...
4.	Lamivudine (3TC)FDA Link 08/01/2000 - "A significant reduction was noted in the morbidity and hospitalizations for complications of liver disease before and after starting lamivudine (1.5+/-0.7 vs. 0.6+/-0.7, p<0.002). " 07/01/2000 - "Liver disease-significant improvement with lamivudine." 11/01/2002 - "Lamivudine has previously been found to be effective not only in patients with compensated liver disease due to hepatitis B virus (HBV) but also in those with hepatic decompensation. " 01/01/2008 - "However, liver dysfunction was not improved by lamivudine. " 05/01/2009 - "Viral suppression with continuous lamivudine therapy reduces the risk of complications and delays progression of liver disease as long as response is maintained." Order ALL the reference details at left...
5.	AntigensIBA 07/01/1990 - "All 21 cleared the antigen during follow-up and liver disease was either mild and asymptomatic (nine cases) or clinically overt (12 cases), but none had life-threatening liver disease. " 03/01/1993 - "Blast cells with Auer rods demonstrated 8;21 translocation lacking 11q with 30 of 30 analyzed bone marrow cells, and the following antigen pattern: CD5+, CD19+, CD33+, CD56+, HLA-DR+. After 4 courses of post remission therapy, the maintenance therapy was discontinued because of his liver dysfunction. " 04/01/1988 - "In several liver diseases qualitative and quantitative changes in the HLA gene product expression can be found on hepatocytes, bile duct epithelium and sinusoidal lining cells and these changes may affect the efficacy of the immune system in recognizing an exogenous antigen. " 05/01/1985 - "We postulate that, in patients with liver disease either increased intestinal uptake resulting in increased humoral response, or decreased hepatic clearance of food antigens intensifying a humoral response to these foreign antigens, may occur." 12/01/1976 - "While persistence of the antigenaemia is associated with persisting liver disease, the converse is not true in that the disappearance of the antigen does not necessarily imply an improvement in liver disease. " Order ALL the reference details at left...
6.	DNA (Deoxyribonucleic Acid)IBA 05/01/1997 - "The results show that in general, the branched DNA assay detects HBV DNA in more patients than hybrid-capture and that this improved detection rate is relevant clinically and genome equivalents/ml are preferred to pg/ml to quantify HBV DNA in clinical specimens and finally qualitative, non-quantitative polymerase chain reaction can detect HBV DNA in patients without evidence of active HBV-related liver disease. " 07/01/2000 - "No TTV infected child [follow-up: 31 (median; range: 6-60) months] showed signs of liver disease; five infants cleared TTV DNA after 22 (median; range: 6-60) months. " 04/01/1999 - "Advances in computer-aided diagnosis, imaging techniques, DNA mutation analysis, virology, immunology and biochemistry have improved our understanding of chronic liver diseases and the possibilities for non-invasive diagnosis. " 11/01/1998 - "Two patients cleared HBV DNA, and their liver disease improved by clinical and histologic criteria. " 11/27/1996 - "Our aim was to test its efficacy when used pre- and posttransplantation in HBV-DNA positive patients with endstage liver disease. " Order ALL the reference details at left...
7.	Hepatitis B Surface Antigens (HBsAg)IBA 05/01/1992 - "Although the frequency of HBsAg loss in treated patients is relatively low, the improvement in liver disease obtained from IFN therapy is sustained over a long period." 03/01/2006 - "Patients who on follow-up cleared HBsAg and/or did not develop any clinical, radiologic, or histologic evidence of chronic liver disease (CLD) were categorized as AVHB (group 1). " 09/01/2005 - "The purpose of the present study was to determine the frequency of hepatitis B virus (HBV) markers in families of HBsAg-positive patients with chronic liver disease. " 04/01/2005 - "STUDY DESIGN: Prospective study of 70 consecutive patients with features of early liver disease or discovered with HBsAg (or anti-HCV) during pre-employment and/ or pre-donation screening at Ile-Ife, Nigeria. " 01/01/2002 - "BACKGROUND: The aim of the present study was to evaluate the clinical characteristics at first hospital consultation, according to the genotype of hepatitis B virus (HBV), in patients with chronic liver diseases and positivity for hepatitis B surface antigen (HBsAg) in metropolitan Tokyo. " Order ALL the reference details at left...
8.	Interferon-alpha (Interferon Alfa)FDA Link 04/01/1996 - "Efficacy of low-dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: a randomized controlled trial." 01/01/1996 - "Efficacy of human leukocyte interferon-alpha treatment in elderly patients with hepatitis-C virus-related chronic liver disease." 03/01/1994 - "Treatment with alfa-interferon (alpha IFN) was added and thereafter, the liver dysfunction improved. " 07/07/2005 - "AIM: To study the expression of interferon-alpha/beta (IFN-alpha/beta) receptor protein in liver of patients with hepatitis C virus (HCV)-related chronic liver disease and its clinical significance. " 11/01/1998 - "In addition, 120 consecutive patients with chronic liver diseases (disease control group), who had never received alpha-interferon therapy, were evaluated during the period of the study (at least for 12 months). " Order ALL the reference details at left...
9.	BilirubinIBA 06/01/1981 - "Clinical features of liver disease on entry into the study were similar in the two groups, and total serum bilirubin and prothrombin time improved more rapidly in the treatment group (p less than 0.05). " 01/01/1983 - "Treatment for cholestatic liver disease (CLD): plasma sorption and filtration for improved bilirubin removal." 01/01/1974 - "Hepatic clearance of unconjugated bilirubin in cholestatic liver diseases." 05/01/2008 - "In the present study, we report a confirmed case of a girl of 1 year of age with increased bilirubin of 28.5 mg/dL and pediatric end-stage liver disease score 20. " 03/01/1999 - "This study was conducted to identify bilirubin in deciduous teeth obtained from two patients with a history of severe liver dysfunction. " Order ALL the reference details at left...
10.	Ribavirin (Virazole)FDA LinkGeneric 01/01/2008 - "PATIENTS AND METHOD: The study subjects were 1,193 patients with HCV-related chronic liver disease and IFN- or IFN plus ribavirin-induced SVR. " 05/01/2000 - "METHODS: Single oral 600 mg doses of ribavirin were administered to healthy male and female volunteers (n = 6) and patients with stable chronic liver disease (n = 17), in a parallel group study. " 05/01/2000 - "AIMS: The primary objective of this study was to describe the single dose pharmacokinetics of ribavirin in subjects with normal liver function and those with various degrees of stable chronic liver disease. " 01/01/2006 - "Combining suboptimal doses of ribavirin (5-10 mg/kg/day) with IFN alfacon-1 (5-10 microg/kg/day), we were able to demonstrate increased protection from mortality, reduced viral burden and liver disease, and greatly extended survival times as compared to treatments where drugs were administered alone. " 01/01/2006 - "In the case of HCV-associated liver diseases, Pegylated IFN (Peg IFN) + ribavirin combination therapy is the standard and most effective treatment with a sustained response of 60-70%. " Order ALL the reference details at left...

Therapies and Procedures

1.	Liver Transplantation 04/27/2009 - "BACKGROUND: Liver transplantation is the best treatment option for endstage liver disease. " 01/01/2007 - "Liver transplantation has emerged as a highly effective treatment for patients with HCC, particularly in the setting of significant underlying liver disease. " 07/01/2004 - "Liver transplantation is currently the best option for HIV-infected patients with end-stage liver disease. " 07/01/2004 - "Orthotopic liver transplantation (OLT) is the best treatment for end-stage liver disease. " 06/01/2001 - "Liver transplantation (LT) is the best treatment for end-stage liver diseases but it entails a high incidence of neuropsychiatric complications. " Order ALL the reference details at left...
2.	Transplantation (Transplant Recipients) 07/01/2003 - "One year posttransplantation, follow-up data from transplant recipients showed significant improvement in most psychological domains relative to both healthy comparison participants and patients with chronic liver disease who did not undergo transplantation. " 01/01/2006 - "Successful cryopreservation of hepatocytes is essential to the future of hepatocyte transplantation as a treatment for liver disease, and also for the improved in vitro use of hepatocytes for research. " 08/01/1996 - "This report suggests that TIPS may be feasible and effective for managing patients with life-threatening liver dysfunction after marrow transplantation." 12/01/2006 - "Recent clinical trials have described promising results of hepatocyte transplantation for acute, acute-on-chronic and metabolic liver disease. " 05/01/2006 - "Journey from hepatocyte transplantation to hepatic stem cells: a novel treatment strategy for liver diseases." Order ALL the reference details at left...
3.	Transplants (Transplant) 08/01/2009 - "In animal models of metabolic liver disease, adopting strategies that provide a selective advantage for transplanted hepatocytes have proved to be highly effective in repopulating recipient livers, and the current relatively poor success rate of hepatocyte transplants in humans can be attributed to the lack of a clinically applicable procedure to induce a similar repopulation of the human liver. " 01/01/2009 - "In animal models of liver disease, adopting strategies to provide a selective advantage for transplanted hepatocytes has proved highly effective in repopulating recipient livers, but the poor success of today's hepatocyte transplants can be attributed to the lack of a clinically applicable procedure to force a similar repopulation of the human liver. " 12/01/2007 - "In animal models of liver disease, adopting strategies to provide a selective advantage for transplanted foetal or adult hepatocytes have proved highly effective in repopulating recipient livers, but the poor success of today's hepatocyte transplants can be attributed to the lack of a clinically applicable procedure to force a similar repopulation of the human liver. " 03/01/1996 - "Newer preservation solutions permit elective timing of the procedure and a clearer understanding of the natural history of the underlying liver disease has helped to define those patients most in need of a transplant earlier in the course of their illness. " 05/01/2009 - "Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft." Order ALL the reference details at left...
4.	Drug Therapy (Chemotherapy) 02/01/2005 - "Although, severe liver dysfunction was observed, the patient achieved a complete remission (CR) on day 31 following chemotherapy and has maintained CR for more than five years. " 03/13/1998 - "Therapy with IFN-alpha for 9 weeks induced a remission in liver disease and complete remission of ML was obtained with subsequent chemotherapy. " 02/01/1989 - "It is difficult, time-consuming, and expensive to evaluate the therapeutic efficacy of regional chemotherapy of metastatic liver disease by means of imaging procedures. " 01/01/2009 - "Facial swelling and liver dysfunction improved immediately, and after five courses of chemotherapy, she achieved partial remission without any severe adverse events. " 09/15/1983 - "Liver disease during chemotherapy and after its completion was studied in 103 leukemic children in long-term remission. " Order ALL the reference details at left...
5.	Highly Active Antiretroviral Therapy (HAART) 01/01/2004 - "Critical liver diseases are now major causes of death in HIV-1-infected patients after the remarkable improvement in the clinical status resulting from highly active antiretroviral therapy. " 02/01/2005 - "With the much-improved survival of HIV-infected patients through the use of highly active antiretroviral therapy, liver disease caused by coinfection with HCV has emerged as a significant threat to the health and survival of persons with HIV disease. " 01/01/2007 - "With improved control of HIV disease with HAART, liver disease has emerged as one of the leading causes of death in patients with HIV Anti-HBV therapy should be considered for all HIV/HBV-coinfected patients with evidence of liver disease, irrespective of the CD4 cell count. " 11/01/2007 - "SUMMARY: Studies evaluating the impact of the early initiation of highly active antiretroviral therapy on liver disease in coinfected patients are urgently needed. " 04/15/2007 - "Eleven cohort studies have shown that HAART is associated with a reduced rate of progression of HCV liver disease, and 4 of these studies have demonstrated a reduction in liver-related mortality. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Liver Diseases

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 855 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>